The recent Nasdaq entrant prepares to move AKY-2519 into the clinic.
ApexOnco Front Page
Recent articles
The phase 2/3 Revival trial will test a ven/aza combo in first-line AML.
The company pays $2.5bn for Day One and its approved drug Ojemda.
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
Ono's antisense therapy is to begin its first pivotal trial.
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
